Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom
Executive Summary
A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.
You may also be interested in...
Galapagos CEO Interview: Independence Allows Us To Keep Innovating
Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would be "unacceptable and unwanted."
Cablivi CHMP Backing Helps Validate Sanofi's €3.9bn Ablynx Purchase
Cablivi is first therapeutic to receive positive CHMP opinion for treating acquired thrombotic thrombocytopenic purpura, a rare blood disorder.
Ablynx Ups Profile Stateside With $200m Nasdaq Listing
Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.